Patient Advocacy

Colin, living with acute hepatic porphyria

Alnylam Advocacy Imperatives

Actively listen to patients and integrate their perspectives across our business

Actively listen to patients and integrate their perspectives across our business

Engage, empower and inspire advocacy groups to meet the needs of patient communities

Engage, empower and inspire advocacy groups to meet the needs of patient communities

Support and partner on patient education and disease awareness programs

Support and partner on patient education and disease awareness programs

Patient Advocacy Around the World

Working in more than 20 countries with over 60 Patient Advocacy Groups (PAGs)

ADVOCACY GROUP LEGEND:

  Acute Hepatic Porphyria
  Hereditary ATTR Amyloidosis
  Primary Hyperoxaluria Type 1
map-pins

Patient Advocacy at Alnylam

 Patient Advocacy at Alnylam
+ +
 Patient Advocacy at Alnylam
+ +
 Patient Advocacy at Alnylam
+ +
 Patient Advocacy at Alnylam
+ +
 Patient Advocacy at Alnylam
+ +
 Patient Advocacy at Alnylam
+ +

Patient Advocacy and Engagement Team

Meet the Patient Advocacy & Engagement Team

TIFFANY PATRICK

Vice President

Cambridge, MA

ALAN NOLAN

Director,

CEMEA Region

Maidenhead, UK

AIKO MIURA

Associate Director,

Asia Pacific Region

Tokyo, Japan

CARA HESSE

Director,

Primary Hyperoxaluria Type 1

Cambridge, MA

FRAN KOCHMAN

Director,

Amyloidosis

Cambridge, MA

THIRUSHA LANE

Senior Manager,

CEMEA Region

Maidenhead, UK

Meet the Patient Advocacy & Engagement Team

TIFFANY PATRICK

Vice President

Cambridge, MA

ALAN NOLAN

Director,

CEMEA Region

Maidenhead, UK

AIKO MIURA

Associate Director,

Asia Pacific Region

Tokyo, Japan

CARA HESSE

Director,

Primary Hyperoxaluria Type 1

Cambridge, MA

FRAN KOCHMAN

Director,

Amyloidosis

Cambridge, MA

THIRUSHA LANE

Senior Manager,

CEMEA Region

Maidenhead, UK

ad

A global grant program that empowers patient advocacy groups to develop innovative solutions to address the unmet needs for the communities they serve.

Additional Alnylam Resources

We are committed to supporting patients and their families throughout their journey with a wide range of programs and services—from diagnosis to access to treatment and care.

We offer a range of patient support services to help those impacted by diseases we are focused on.

Learn More ›

We believe that people who may benefit from our innovative medicines should be able to access them and this guides the actions we take as a company.

Learn More ›

Our medicines, based on RNA interference (RNAi), represent an innovative new approach to treating disease.

Learn More ›

Hereditary ATTR amyloidosis is a rare, inherited genetic disease caused featuring a wide variety of nervous system, cardiac, and digestive symptoms.

Learn More ›

In certain circumstances, we work with physicians to make our investigational therapies available to patients who might not be otherwise eligible for or have access to them.

Learn More ›

We are currently running several different clinical trials for diseases across multiple therapeutic areas.

Learn More ›

Acute hepatic porphyria (AHP) refers to a family of ultra-rare, genetic diseases characterized by potentially life-threatening attacks and, for some patients, chronic manifestations.

Learn More ›

Primary hyperoxaluria type 1 (PH1) is an ultra-rare genetic disease that leads to frequent kidney stones, progressive kidney disease, and multi-organ dysfunction.

Learn More ›

Understanding RNAi

RNA interference (RNAi) is the core discovery that forms the therapies Alnylam is developing. It is recognized as a major scientific breakthrough—but how does it work, exactly?

Learn About How RNAi-Based Medicines Work

Visit the Alnylam Newsroom ›

SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.